Curis (NASDAQ:CRIS) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Curis (NASDAQ:CRIS) to a hold rating in a research report report published on Saturday morning.

Several other research firms also recently weighed in on CRIS. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Curis in a research report on Friday, March 20th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Curis presently has an average rating of “Hold” and an average price target of $17.00.

Curis Price Performance

Shares of NASDAQ:CRIS opened at $0.56 on Friday. Curis has a 12 month low of $0.52 and a 12 month high of $3.13. The firm has a market capitalization of $7.63 million, a P/E ratio of -0.47 and a beta of 3.02. The company’s fifty day moving average price is $0.95 and its 200 day moving average price is $1.21.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, March 19th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $3.25 million. On average, sell-side analysts anticipate that Curis will post -7.12 EPS for the current year.

Institutional Investors Weigh In On Curis

Institutional investors and hedge funds have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Curis by 2,883,237.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after buying an additional 230,659 shares during the last quarter. CM Management LLC raised its stake in Curis by 47.7% during the 3rd quarter. CM Management LLC now owns 325,000 shares of the biotechnology company’s stock valued at $540,000 after acquiring an additional 105,000 shares during the last quarter. Armistice Capital LLC raised its stake in Curis by 8.7% during the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after acquiring an additional 78,265 shares during the last quarter. Renaissance Technologies LLC lifted its position in Curis by 37.3% during the 4th quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 65,404 shares during the period. Finally, Maverick Capital Ltd. lifted its position in Curis by 7.8% during the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after acquiring an additional 49,554 shares during the period. 29.97% of the stock is owned by hedge funds and other institutional investors.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.